We are developing products for dermal/wound healing applications, respiratory and critical care, with our lead developments in chronic wound care.
NHS Research Ethics Committee approved studies:
NOx has demonstrated potent, broad-spectrum, anti-microbial activity.
Pre-clinical, data on file: NOx prevented biofilm formation, and was effective in treating established biofilms, for all antibiotic resistant and sensitive bacteria screened.
Additional pre-clinical investigations are ongoing.
Redefining Wound Care
Our revolutionary, disruptive, topical wound treatment system leverages the anti-microbial and healing properties of the NO pathway.
Our NOx wound treatment system uniquely provides a moist wound environment, which absorbs wound fluid, prevents infection, increases blood flow, and accelerates healing.
We believe this will significantly improve healing whilst reducing serious adverse outcomes, such as diabetes-related amputations.
“Every 30 minutes, a limb is lost due to a landmine. Every 30 seconds, a limb is lost due to diabetes”
Bharara et al. Int Wound J, 2009
Our most advanced developments are in diabetic foot ulcers. ProNOx1, our Phase III study investigating the safety and efficacy of NOx in diabetic foot ulcers, in 144 participants across sites in the UK is now closed, with results being prepared for a high impact publication.
for chronic and acute wounds
for chronic and acute wounds
We are expanding the clinical evidence of NOx in chronic and acute wound care, with NHS Research Ethics Committee approved clinical studies approved and awaiting to start.
The NOx wound treatment system provides a moist wound environment, while the hydrogel layer absorbs wound fluid, provides protection from further friction and pressure, and releases sustained NO to accelerate healing and prevent infection.
Venous Leg Ulcers
Approximately 2% of the population may experience venous leg ulcers in their lifetime – 60% of these ulcers take longer than 2 years to heal.
Leg Ulcers relating to Sickle Cell Disease
Leg ulcers can be a chronic, difficult-to-treat complication for patients living with sickle cell disease. In the US, approximately 100,000 people live with sickle cell disease, with up to 25% of these patients developing lower extremity ulcers.
The NOx wound treatment system is currently being used in a compassionate use programme.
There is a 33% incidence of pressure ulcers in critical care units, and 66% incidence amongst elderly patients admitted to acute care hospitals for non-elective orthopaedic procedures.
The NOx wound treatment system has been designed to be non-adherent over the wound bed, allowing for easy removal. Combined with its potent anti-microbial activity, there is a real opportunity to make a significant different in the acute wound care setting.
Approximately 6 million minor burns are treated medically each year worldwide.
There are approximately 100 million surgical incisions per year, and approximately 50 million traumatic wounds, with surgical site infection well recognised as a serious ongoing problem in the safe recovery and healing of wounds.
Our NOx wound treatment platform, currently based on a highly absorbent sheet hydrogel, can be delivered on fibre, foam and hydrocolloid based dressings.
The NOx system provides potent anti-microbial activity, with potential to enhance the local effects of systemic antibiotics and treat micro-organism led dermatological conditions.
Acne vulgaris, commonly caused by excessive growth of the bacteria Propionibacterium, is one of the top ten most prevalent diseases worldwide, affecting more than 630 million people worldwide.
Fungal nail infections (onychomycosis)
One of the hardest to treat superficial fungal infections, onychomycosis is a common dermatological condition affecting up to 26% people worldwide.
Atopic eczema (atopic dermatitis)
Atopic dermatitis is the most common form of eczema, a long- term skin disease, particularly prevalent in children, affecting 15-20% of children worldwide.
The number and efficacy of commercially available products for transdermal delivery is limited.
As well as stimulating local vasodilation, NO regulates intercellular adhesion and increases blood vessel permeability. We believe our NOx system will allow the transdermal application of large molecules that cannot currently be administered across the skin barrier.
Potential benefits include:
As the most prevalent nosocomial infection in Critical Care Units worldwide, VAP accounts for more than half of all Intensive Care Unit-acquired infections, with mortality rates ranging from 14-70%.
Our NOx system generates large amounts of NO, protecting the mucosal lining through its potent anti-microbial activities, and can be locally delivered to target tissues.
NOVAP, our Phase I dose finding study in mechanically ventilated patients demonstrated the safety of the NOx system and the ability to deliver NO to the stomach, oesophagus and mouth.
We propose that our NOx solution has the unique potential to prevent VAP by protecting the gastric and oropharyngeal colonisation from pathogenic bacteria, which would otherwise spread to the lungs.
Septic shock and severe sepsis occur as a result of infection and resulting organ dysfunction, with patients becoming critically unwell, requiring intensive care.
Septic shock has been characterised by marked alterations of microcirculatory blood flow which, if a patient survives, can lead to permanent loss of limb function and extremity amputation, for example, as seen as a severe complication in paediatric meningitis.
We propose to use our NOx dressing system to increase local peripheral circulation to reduce the risk of limb damage. ProNOx4, our Phase I proof-of-concept study, assessing whether the NOx dressing system can improve peripheral circulation in patients with septic shock, is approved by the NHS Research Ethics Committee and awaiting MHRA approval
In the US, there are approximately 1000 new diagnoses of cystic fibrosis each year. The most common presentation of cystic fibrosis is with respiratory problems, usually recurrent lower respiratory tract infection with chronic sputum production.
We know from a previous healthy volunteer trial, RespiNOs, that we can deliver a safe, well-tolerated nebulised acidified nitrite to the lungs which then releases NO in situ. We also know that the NOx system is highly effective against Pseudomonas aeruginosa, the main pathogen responsible for lower respiratory tract infections.
The intrinsic properties of NO could have many beneficial effects, including enhancement of ciliary function and prevention of bacterial colonisation of the lungs, and therefore reduce symptoms of cystic fibrosis.